ZVSA News and Press, ZyVersa Therapeutics Inc. From 08/08/25

Hudson Global Inc. (HSON) is expected to report $0.17 for Q2 2025 Meritage Hospitality Group Inc. (MHGU) is expected to report $0.54 for Q2 2025 Genprex Inc. (GNPX) is expected to report for Q2 2025 Hour Loop Inc. (HOUR) is expected to report for Q2 2025 New Fortress Energy Inc. (...

ZyVersa Therapeutics Inc. (ZVSA) is expected to report for Q2 2025

2025-08-07 18:45:20 ET ZyVersa Therapeutics, Inc. (ZVSA) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 2.10%. The average open to low on the day of earnings was -4.99%. The average ope...

2025-08-07 18:40:20 ET ZyVersa Therapeutics, Inc. (ZVSA) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in ZVSA stock price following earnings has averaged ±2.76% , with a median of 0.99...

WESTON, Fla., July 21, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, ann...

2025-07-08 14:00:35 ET ZyVersa Therapeutics Surges 126% on FDA Compassionate Use for Ultra-Rare Kidney Disease ZyVersa Therapeutics, Inc. ( ZVSA ) soared 125.67% to lead the PRISM Emerging Biotech Index after the FDA approved emergency compassionate use of its investigational ...

2025-07-08 13:01:35 ET Patient with progressive kidney disease receives FDA-authorized compassionate use of VAR 200 under care of University of Miami nephrologist and drug inventor ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA ), a clinical-stage biopharmaceutical company focused on firs...

WESTON, Fla., July 08, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, tod...

2025-07-08 08:50:34 ET DENVER, Colo., Jul 08, 2025 ( 247marketnews.com )- ZyVersa (NASDAQ:ZVSA) announced its support for the FDA-authorized Emergency Compassionate Use of its investigational drug Cholesterol Efflux Mediator VAR 200 in a patient diagnosed with ApoCII amyloidos...

ApoCII amyloidosis, resulting from abnormal organ deposition of toxic fibrillar amyloid proteins, is an ultra-rare condition that mostly affects the kidneys and manifests with protein spillage into the urine (proteinuria) and chronic kidney disease. Despite being treated with standard-of-care...